Natco Pharma submits application with USFDA for generic cancer drug

Jubilant Pharmova | CMP: Rs 342 | The stock price ended in the red after the firm reported loss of Rs 15.67 crore in the quarter ended December 2022 versus profit of Rs 50.9 crore. Revenue is up 18.5 percent at Rs 1,552.5 crore versus Rs 1,310.5 crore, YoY.

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

live

• bselive
• nselive

Volume

Todays L/H

More

×

Natco Pharma on Monday said it has submitted a new application with the US health regulator for marketing authorisation of the generic version of Olaparib tablets, used in treating certain forms of ovarian, breast, pancreatic and prostate cancers.

The company has submitted an Abbreviated New Drug Application (ANDA) containing a 'paragraph IV' certification with the US Food and Drug Administration (FDA) for the product, a generic version of AstraZeneca's Olaparib tablets in strengths of 100mg and 150mg.

Olaparib tablets are marketed in the US by AstraZeneca under brand Lynparza. Natco Pharma said it has been named as defendant in a lawsuit filed in the US district court of New Jersey by AstraZeneca and Kudos Pharmaceuticals.

"Natco and its co-development and marketing partner Alembic Pharmaceuticals believe that the ANDA is possibly sole first-to-file based on its filing date and may be eligible for 180 days of marketing exclusivity at the time of launch of the product," it added.

As per AstraZeneca, Lynparza recorded sales of USD 1,226 million in the US market for the year ended December 2022. Natco shares were trading 2.2 per cent up at Rs 537.50 apiece on the BSE.